All lobbying filings

Orchard Therapeutics North America

Orchard Therapeutics North America filed a Q2 amendment for Orchard Therapeutics North America on March 13, 2026.

Lobbying for Orchard Therapeutics North America · Health

As filed: ORCHARD THERAPEUTICS NORTH AMERICA for ORCHARD THERAPEUTICS NORTH AMERICA.

All filings by Orchard Therapeutics North America · Everything Orchard Therapeutics North America has reported

Filing · LD-2 quarterly report Q2 amendment

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Mar 13, 2026

Expenses

$430,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Appropriations for Newborn Screening HR 1262/ S 932 - Give Kids a Chance Act of 2025

Medicare/Medicaid

Medicaid Value-Based Payments for Patients (MVP) Act HR 1509/ S 752 - Accelerating Kids' Access to Care Act & Give Kids a Chance Act 2025

Bills named in this filing 2

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
H.R. 1509
Accelerating Kids’ Access to Care Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.